Patrys is a publicly-listed company on the Australian Securities Exchange (ASX:PAB).  The Company's headquarters are in Melbourne, Australia, and our main R&D center is in Würzburg, Germany, where our technology platform and product pipeline was first developed.

Our principal focus is on the development of a completely new type of product for the treatment of cancer – natural human antibodies.  These natural human antibodies offer the promise of increased potency coupled with greater safety as compared to existing cancer treatments.

The Company's most mature product is PAT-SC1, that has been shown to provide treated gastric cancer patients with a survival benefit, and which is now being prepared for extended human trials.

Patrys has also now advanced a second product successfully into the clinic: in July of 2010 Patrys received regulatory approval to evaluate PAT-SM6 in a first-in-human clinical trial for the treatment of melanoma patients.  This trial was recently completed in February 2012 with promising results.

Planning for a second trial for PAT-SM6 is currently underway in the area of multiple myeloma.

In addition to PAT-SC1 and PAT-SM6, Patrys has a deep pipeline of other promising products, which Patrys has extended by adding on average two new products to the pipeline per year.

The blend of internal and partnered programs, when coupled with a first-move position in the natural human antibody space, presents the Company with a diverse number of value drives going forward.

Click here to download a copy of the Patrys’ Company Profile

What we offer - revolutionary cancer therapeutics

There is a major problem in the cancer field.

The survival rates for many cancers have not changed over the past decade.

This is due in part to a focus on making incremental improvements to existing treatments like chemotherapy and radiation – that continue to be largely ineffective and unsafe.

Patrys intends to break the current paradigm by developing a completely new type of product for the treatment of cancer – natural human antibodies.

Compared to existing cancer treatments, Patrys’ natural human antibodies offer differentiating and potentially valuable product features, including:

• 100% human composition, reducing the risk of immune rejection and potentially offering greater potency.
• Attacking cancer cells while leaving healthy tissue unharmed, in turn offering a safer treatment profile.
• Killing cancer cells via different mechanisms to currently marketed and largely ineffective treatments (i.e., each Patrys antibody binds to a newly discovered and proprietary disease target).
• Being potentially effective across the spectrum of patients, regardless of age, gender or stage of disease.
• Being applicable to many different deadly cancers, including melanoma, gastric cancer and pancreatic cancer.

View Product Pipeline

Intellectual Property

As of October 2010, Patrys’ patent portfolio includes multiple patent families.   The portfolio covers all lead products, and patents have already been issued in all major markets including the United States, Europe, Japan, Canada, and Australia.  These filings cover our novel antibodies, newly discovered disease targets, and production technologies.  To date, on average the Company files three new patent families per year that cover new products, targets and supporting technologies.